Accumulating evidence has revealed that FAP + CAFs might provide a more immunosuppressive microenvironment to resist damage from immunocytes/radiotherapy/chemotherapy, resulting in increased tumor survival (Yang et al., 2016; Lindner et al., 2018; Ansems and Span, 2020). The gene discussed is FAP; the disease is neoplasm.